Clinical Development

Top message

 

Realize true social contribution through the development of " the best possible products to protect the health and wellbeing of the people. "

 

Drug Development and Regulatory Science Division

Senior Vice President, Dr. Takeki Uehara

Senior Vice President, Dr. Takeki Uehara

In 2002, joined SHIONOGI & Co., Ltd.

Engaged in toxicology research of candidate medicines under development at the Drug Development Research Division / Drug Safety Department.

In 2009, after completing a carrier as a visiting researcher for Public Health research at University of North Carolina at Chapel Hill in the United States, was mainly involved in global development projects as a non-clinical toxicity expert in Shionogi HQ.

In 2013, transferred to the Drug Development and Regulatory Science Division. Successively held the posts of Non-clinical leader of anti-influenza virus drug XOFLUZA, global project leader after obtaining Proof of Concept.

In 2020, transferred to USA Shionogi Inc. Head of Clinical Development Department

In 2021, concurrently serves as Vice President of Clinical Research Department, Global Head of Clinical Operations, and Global Project Leader for S-217622, an oral treatment for COVID-19.

In July 2022, appointed as Senior Vice President of Drug Development and Regulatory Science Division (current position).

 

What is the current state and future of the Drug Development and Regulatory Science Division, which the general manager talks about?

  • Global Development Division’s Vision and Strategy

    Shionogi is conducting global drug development under the slogan of "understanding true needs" and "challenging our speed."

    more
  • Clinical Trials Information

    Find disclosed information on Shionogi sponsored clinical trials here.

    more